1. Scrip
  2. >>Business

Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge

 
• By Anju Ghangurde

Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.  

Horses
Indian market for sacubitril/valsartan grows sharply • Source: Shutterstock

The Indian market for the sacubitril/valsartan combination appears to be growing in leaps and bounds, suggesting that Novartis AG’s efforts to expand reach and access for its heart failure therapy via partnerships is paying dividends. Nevertheless, the shadow of an ongoing suit for a cut-price version of the product looms.

Novartis’s Entresto (sacubitril/valsartan) is sold as Vymada in India, along with its second brands Cidmus and Azmarda, marketed by

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.